Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Grimm on the Brain Cancer Predictive Marker MGMT

November 4th 2011

Dr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer

Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer

October 26th 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Guidelines for Genetic Counseling or BRCA 1/2 Testing Are Often Ignored

October 25th 2011

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

Dr. Mills Discusses the Field of Targeted Therapeutics

October 18th 2011

Dr. Gordon B. Mills from the University of Texas MD Anderson Cancer Center Discusses the Field of Targeted Therapeutics

Resistance Strategies in Focus: Combinations Target Multiple Pathways

October 17th 2011

Advances in the understanding of tumor biology and a robust drug development pipeline are combining to form a 'perfect storm' of opportunity for personalized cancer research to make a leap forward.

Dr. Goy Highlights Recent Advances in Oncology

October 14th 2011

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

The Duke Cancer Institute: A Vehicle for Hope

October 14th 2011

For more than 75 years, the cancer programs of Duke University Medical Center in Durham, North Carolina, have been at the forefront of research and patient care.

Dr. Iruela-Arispe on the Dr. Paul Janssen Award Symposium

October 13th 2011

Dr. Luisa Iruela-Arispe from University of California, Los Angeles on the Dr. Paul Janssen Award Symposium

Dr. Scagliotti on the Future of Multiple Gene Profiles

October 12th 2011

Dr. Giorgio Scagliotti from the University of Turin Discusses the Future of Multiple Gene Profiles

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

October 11th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Efforts to Improve HER2 Testing Continue ASCO Panelist Sees Progress

October 11th 2011

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

The Complexities of Inhibiting Angiogenesis Emerge

October 10th 2011

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

Dr. Scagliotti on Mechanisms of Resistance to EGFR TKIs

October 7th 2011

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Mills on the Development of Combination Therapies

October 7th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses the Development of Combination Therapies

Research Interest in Bevacizumab Remains Robust

October 6th 2011

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Dr. Langer Discusses the JMEN Maintenance Pemetrexed Trial

October 6th 2011

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. McDonald on the Continued Understanding of Bevacizumab

October 6th 2011

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab

A Look Into the Future of Breast Cancer: A Conversation With Joyce A. O'Shaughnessy, MD

October 6th 2011

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

5 Questions for Nita Maihle, PhD

October 5th 2011

Nita Maihle, PhD, is a professor of Obstetrics, Gynecology and Reproductive Sciences, and director of a clinically oriented cancer research laboratory at Yale University, New Haven, Connecticut.

Dr. Rugo on Proliferation as an Anti-Angiogenesis Marker

October 5th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker